Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by David W. Dawson
Based on 54 articles published since 2010
(Why 54 articles?)

Between 2010 and 2020, D. Dawson wrote the following 54 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
Pages: 1 · 2 · 3
51 Article Quercetin aglycone is bioavailable in murine pancreas and pancreatic xenografts. 2010

Zhang, Lifeng / Angst, Eliane / Park, Jenny L / Moro, Aune / Dawson, David W / Reber, Howard A / Eibl, Guido / Hines, O Joe / Go, Vay-Liang W / Lu, Qing-Yi. ·Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA. ·J Agric Food Chem · Pubmed #20499918.

ABSTRACT: Quercetin is a potential chemopreventive and chemotherapeutic agent for pancreatic and other cancers. This study examined the distribution of quercetin in plasma, lung, liver, pancreas, and pancreatic cancer xenografts in a murine in vivo model and the uptake of quercetin in pancreatic cancer MiaPaCa-2 cells in a cellular in vitro model. Mice were randomly allocated to control or 0.2 and 1% quercetin diet groups utilizing the AIN93G-based diet (n = 12 per group) for 6 weeks. In addition, 6 mice from each group were injected weekly with the chemotherapeutic drug gemcitabine (120 mg/kg mouse, ip). MiaPaCa cells were collected from culture medium after cells were exposed to 30 muM quercetin for 0.5, 1, 2, 4, 8, and 24 h. Levels of quercetin and 3-O'-methylquercetin in mouse tissues and MiaPaCa-2 cells were measured by high-pressure liquid chromatography following enzymatic hydrolysis and then extraction. The study showed that quercetin is accumulated in pancreatic cancer cells and is absorbed in the circulating system, tumors, and tissues of pancreas, liver, and lung in vivo. A higher proportion of total quercetin found in tumors and pancreas is aglycones. Gemcitabine cotreatment with quercetin reduced absorption of quercetin in the mouse circulatory system and liver. Results from the study provide important information on the interpretation of the chemotherapeutic efficacy of quercetin.

52 Article Epigenetic regulation affects N-myc downstream-regulated gene 1 expression indirectly in pancreatic cancer cells. 2010

Angst, Eliane / Dawson, David W / Nguyen, Anne / Park, Jenny / Go, Vay L W / Reber, Howard A / Hines, Oscar Joe / Eibl, Guido. ·Hirshberg Laboratories for Pancreatic Cancer Research, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. eliane.angst@gmail.com ·Pancreas · Pubmed #20173668.

ABSTRACT: OBJECTIVES: N-myc downstream-regulated gene 1 (NDRG1), important in tumor growth and metastasis, has recently gained interest as a potential therapeutic target. Loss of NDRG1 expression is generally associated with poor clinical outcome in pancreatic cancer (PaCa) patients. As the NDRG1 gene possesses a large promoter CpG island, we sought to determine whether its repression is epigenetically mediated in PaCa cells. METHODS: Pancreatic cancer cells were treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor trichostatin A. Promoter methylation was assessed by genomic bisulfite sequencing and by combined bisulfite restriction analyses. RESULTS: Treatment with 5-aza-2'-deoxycytidine and trichostatin A enhanced NDRG1 protein expression, implicating epigenetic regulation of NDRG1. However, there was no significant DNA methylation of the NDRG1 promoter CpG island, as determined by genomic bisulfite sequencing of HPAF-II cells. We further confirmed the lack of promoter methylation in 6 PaCa cell lines by combined bisulfite restriction analyses. CONCLUSIONS: These findings indicate that NDRG1 gene reactivation in PaCa cell lines by pharmacologic reversal of DNA methylation and histone deacetylation occurs via an indirect mechanism. This may occur via the altered expression of genes involved in the regulation of NDRG1 transcription or NDRG1 protein stability in PaCa cells.

53 Article Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. 2010

Manuyakorn, Ananya / Paulus, Rebecca / Farrell, James / Dawson, Nicole A / Tze, Sheila / Cheung-Lau, Gardenia / Hines, Oscar Joe / Reber, Howard / Seligson, David B / Horvath, Steve / Kurdistani, Siavash K / Guha, Chandhan / Dawson, David W. ·Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. ·J Clin Oncol · Pubmed #20142597.

ABSTRACT: PURPOSE Differences in cellular levels of histone modifications have predicted clinical outcome in certain cancers. Here, we studied the prognostic and predictive value of three histone modifications in pancreatic adenocarcinoma. METHODS Tissue microarrays (TMAs) from two pancreatic adenocarcinoma cohorts were examined, including those from a 195-patient cohort from Radiation Therapy Oncology Group trial RTOG 9704, a multicenter, phase III, randomized treatment trial comparing adjuvant gemcitabine with fluorouracil and a 140-patient cohort of patients with stage I or II cancer from University of California, Los Angeles Medical Center. Immunohistochemistry was performed for histone H3 lysine 4 dimethylation (H3K4me2), histone H3 lysine 9 dimethylation (H3K9me2), and histone H3 lysine 18 acetylation (H3K18ac). Positive tumor cell staining for each histone modification was used to classify patients into low- and high-staining groups, which were related to clinicopathologic parameters and clinical outcome measures. Results Low cellular levels of H3K4me2, H3K9me2, or H3K18ac were each significant and independent predictors of poor survival in univariate and multivariate models, and combined low levels of H3K4me2 and/or H3K18ac were the most significant predictor of overall survival (hazard ratio, 2.93; 95% CI, 1.78 to 4.82) in the University of California, Los Angeles cohort. In subgroup analyses, histone levels were predictive of survival specifically for those patients with node-negative cancer or for those patients receiving adjuvant fluorouracil, but not gemcitabine, in RTOG 9704. CONCLUSION Cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic adenocarcinoma with distinct epigenetic phenotypes and clinical outcomes and represent prognostic and predictive biomarkers that could inform clinical decisions, including the use of fluorouracil chemotherapy.

54 Minor Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas. 2017

Sugimoto, Motokazu / Hines, O Joe / Dawson, David W / Muthusamy, V Raman / Reber, Howard A / Donahue, Timothy R. ·Department of Surgery, UCLA Medical Center, Los Angeles, CA Department of Pathology and Laboratory Medicine, UCLA Medical Center, Los Angeles, CA Division of Digestive Diseases, UCLA Medical Center, Los Angeles, CA Department of Surgery, UCLA Medical Center, Los Angeles, CA, tdonahue@mednet.ucla.edu. ·Pancreas · Pubmed #28291165.

ABSTRACT: -- No abstract --